Download Full Text (2.9 MB)
galectin, muscular dystrophy, protein therapy
- Limb-Girdle Muscular Dystrophy 2B (LGMD2B) belongs to a group of diseases called dysferlinopathies, caused by mutations in the DYSF gene.
- Dysferlin is an important muscle membrane protein involved in repair and regeneration after injury.
- LGMD2B causes muscle wasting, fat infiltration, and loss of ambulation in patients.
- Currently there is no cure and few treatment options.
- Galectin-1 is a small protein that interacts with glycosylated proteins. It shows efficacy in treating murine models of Duchenne Muscular Dystrophy.
- Here we explore the ability of recombinant human Galectin-1 (rHsGal-1) to ameliorate disease pathologies and mechanisms of LGMD2B
Hypothesis: Recombinant human galectin-1 (rHsGal-1) protein treatment will improve membrane repair of LGMD2B models thus increasing myogenesis, stabilizing muscle integrity, and decreasing disease manifestation.
BYU ScholarsArchive Citation
Vallecillo, Mary L.; Teynor, Matthew S.; Valdoz, Jonard C.; Hayes, Spencer D.; Poulson, P. Daniel; Rathgeber, Matthew F.; Stowell, Sean R.; and Van Ry, Pam M., "Galectin-1: A Potential Protein Therapy for Limb-Girdle Muscular Dystrophy 2B" (2020). Library/Life Sciences Undergraduate Poster Competition 2020. 28.
Physical and Mathematical Sciences
Chemistry and Biochemistry
Copyright Use Information